Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2025

Revenue Recognition

Schedule of disaggregation of revenue

	Three Months Ended March 31,
	2025		2024
Collaborative revenue
CSL Vifor (KORSUVA injection profit sharing)	$	1,198	$	788
Total collaborative revenue	$	1,198	$	788
Commercial supply revenue
CSL Vifor (KORSUVA injection)	$	—	$	640
Total commercial supply revenue	$	—	$	640
Clinical compound revenue
Maruishi	$	48	$	84
Total clinical compound revenue	$	48	$	84
Other revenue (non-cash)
CSL Vifor (Kapruvia ex-U.S.)	$	373	$	290
Maruishi		950		333
Total other revenue	$	1,323	$	623